CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Gemcitabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03910387
NCT03910387Phase 2Completed
CompareCT.gov

Weight Loss in Patients With Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat Ethyl

Emory University·interventional·Posted Apr 10, 2019·Updated Dec 16, 2025

In Brief

A Phase 2 clinical trial evaluating Gemcitabine, Nab-paclitaxel, and 1 other intervention for Locally Advanced Unresectable Pancreatic Adenocarcinoma and 4 related conditions. Completed, enrolled 23 participants across 3 sites.

Detailed Summary

This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Lexicon Pharmaceuticals

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 10, 2019
Enrollment StartApr 17, 2019
Primary CompletionJun 29, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.2 years ago

Interventions

Gemcitabinedrug

Given gemcitabine/nab-paclitaxel combination therapy

Nab-paclitaxeldrug

Given gemcitabine/nab-paclitaxel combination therapy

Telotristat Ethyldrug

Given PO